| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2011 | WO2010132861A3 Diagnostic and treatment for chronic and acute phase myeloid leukemia |
| 01/27/2011 | WO2010130462A3 Phosphate-free pharmaceutical composition for the treatment of glaucoma |
| 01/27/2011 | WO2010130424A9 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| 01/27/2011 | WO2010119455A3 An injectable sustained release pharmaceutical composition |
| 01/27/2011 | WO2010118063A3 Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
| 01/27/2011 | WO2010113179A3 Process for purifying eslicarbazepine acetate |
| 01/27/2011 | WO2010112848A3 Inhibition of biofilm organisms |
| 01/27/2011 | WO2010105048A9 Thiazolidinedione analogues |
| 01/27/2011 | WO2010104324A3 Halogenated isoindole compounds with superior binding affinity to beta-amyloid aggregates and fibrils, method for preparing same, and use thereof |
| 01/27/2011 | WO2010101538A3 New crystalline forms of tiotropium bromide |
| 01/27/2011 | WO2010099445A3 Non-covalent inhibition of the 26s proteasome and uses thereof |
| 01/27/2011 | WO2010084050A3 Quinazolinone derivatives useful as vanilloid antagonists |
| 01/27/2011 | WO2010082212A3 N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses |
| 01/27/2011 | WO2010073124A3 Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof |
| 01/27/2011 | WO2010056630A8 Triazolopyrimidinones and methods of use thereof |
| 01/27/2011 | WO2010051196A8 Novel substituted azabenzoxazoles |
| 01/27/2011 | WO2010027996A9 Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity |
| 01/27/2011 | WO2010021918A8 Compounds as kinase inhibitors |
| 01/27/2011 | WO2010009065A3 Amphipathic peptide compositions |
| 01/27/2011 | WO2010008474A4 Methods for treating multiple sclerosis using antisense oligonucleotides |
| 01/27/2011 | WO2010004579A3 Orally active curcuminoid compounds |
| 01/27/2011 | WO2009158371A8 Inhibitors of akt activity |
| 01/27/2011 | WO2009154777A9 Process for preparing and drying solid rasagiline base |
| 01/27/2011 | WO2009116069A3 Process for preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(2- methoxyphenoxy) ethyl] amino]-2-propanol |
| 01/27/2011 | WO2009085880A8 C-21 thioethers as glucocorticoid receptor agonists |
| 01/27/2011 | US20110023155 Novel dna fragment and use thereof |
| 01/27/2011 | US20110023137 Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| 01/27/2011 | US20110023135 Use of a new gene coding for a new member of the mcm2-8 family in pharmaceutical compositions |
| 01/27/2011 | US20110021981 Methods And Compositions For Treating Trauma-Hemorrhage Using Estrogen And Derivatives Thereof |
| 01/27/2011 | US20110021972 Composition and Device Structure For Iontophoresis |
| 01/27/2011 | US20110021805 Compounds for treatment of cell proliferative diseases |
| 01/27/2011 | US20110021785 Novel indole derivatives as selective androgen receptor modulators (sarms) |
| 01/27/2011 | US20110021772 New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents |
| 01/27/2011 | US20110021766 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation |
| 01/27/2011 | US20110021752 Tropoelastin Derivatives |
| 01/27/2011 | US20110021641 Suspension formulation for carbon adsorbents |
| 01/27/2011 | US20110021640 Mechanism-based biochemical standardization of resveratrol products and their uses thereof |
| 01/27/2011 | US20110021639 Microbially stable dispersion medium for emulsions |
| 01/27/2011 | US20110021638 Modulation of inflammation by hops fractions and derivatives |
| 01/27/2011 | US20110021637 Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
| 01/27/2011 | US20110021636 Method for crystallization of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride |
| 01/27/2011 | US20110021635 Rbm3 as a marker for breast cancer prognosis |
| 01/27/2011 | US20110021634 Processes for preparing metformin hydrochloride |
| 01/27/2011 | US20110021633 Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States |
| 01/27/2011 | US20110021632 Use of creatine or creatine compounds for skin preservation |
| 01/27/2011 | US20110021631 Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms |
| 01/27/2011 | US20110021630 Method for treating wounds by administering fullerenes |
| 01/27/2011 | US20110021629 Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| 01/27/2011 | US20110021628 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
| 01/27/2011 | US20110021626 Encapsulation of vitamin c into water soluble dendrimers |
| 01/27/2011 | US20110021625 Neuronal cell death inhibitor |
| 01/27/2011 | US20110021624 Alpha-Amino-N-Substituted Amides, Pharmaceutical Composition Containing Them and Uses Thereof |
| 01/27/2011 | US20110021623 System and methods of melanoma prevention |
| 01/27/2011 | US20110021622 Stabilized Synthetic Brood Pheromone and Race-Specific Ratios of Components for Manipulating the Behavior and Physiology of Honey Bees |
| 01/27/2011 | US20110021621 Drug for treating circulatory insufficiency |
| 01/27/2011 | US20110021620 Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| 01/27/2011 | US20110021619 External preparation for skin containing flavanone derivative |
| 01/27/2011 | US20110021618 Methods of treating fibrotic disorders |
| 01/27/2011 | US20110021617 Medicinal Acidic Cannabinoids |
| 01/27/2011 | US20110021616 Halogenated rhodamine derivatives and applications thereof |
| 01/27/2011 | US20110021614 Use of silymarin and silybin in the treatment of neural injury |
| 01/27/2011 | US20110021613 Plants extracts for use in brain modulation |
| 01/27/2011 | US20110021612 Nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use |
| 01/27/2011 | US20110021611 Efficient cell culture system for hepatitis c virus genotype 5a |
| 01/27/2011 | US20110021610 Aromatic prenyltransferase from hop |
| 01/27/2011 | US20110021608 Methods for nucleic acid transfer into cells |
| 01/27/2011 | US20110021607 Methods and Compositions Relating to Carcinoma Stem Cells |
| 01/27/2011 | US20110021606 RNAi Modulation of RSV, PIV and Other Respiratory Viruses and Uses Thereof |
| 01/27/2011 | US20110021605 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 01/27/2011 | US20110021604 Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna |
| 01/27/2011 | US20110021603 TRPM-2 Antisense Therapy |
| 01/27/2011 | US20110021602 Graft polymers for enhanced intracellular delivery of antisense molecules |
| 01/27/2011 | US20110021601 Composition containing microrna-21 inhibitor for enhancing radiation sensitivity |
| 01/27/2011 | US20110021600 Novel nucleic acid |
| 01/27/2011 | US20110021599 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
| 01/27/2011 | US20110021598 Controlled release formulations |
| 01/27/2011 | US20110021597 3-phenoxymethylpyrrolidine compounds |
| 01/27/2011 | US20110021596 Topical therapy for migraine |
| 01/27/2011 | US20110021595 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 01/27/2011 | US20110021594 Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof |
| 01/27/2011 | US20110021593 Novel crystal of substituted phenylalkanoic acid ester and process for producing the same |
| 01/27/2011 | US20110021592 Organic nanoparticles obtained from microemulsions by solvent evaporation |
| 01/27/2011 | US20110021591 Phenylbutazone carrier formulation showing increased bioactivity in animals |
| 01/27/2011 | US20110021590 Aminopyrrolidinone derivatives and uses thereof |
| 01/27/2011 | US20110021589 Imidazolic compounds and use thereof as alpha-2 adrenergic receptors |
| 01/27/2011 | US20110021588 Sublingual dexmeditomidine compositions and methods of use thereof |
| 01/27/2011 | US20110021586 Phenyl-sulfamates as aromatase inhibitors |
| 01/27/2011 | US20110021585 Dual-acting antihypertensive agents |
| 01/27/2011 | US20110021584 Methods and Assays for Detecting and Treating Hypoglycemia |
| 01/27/2011 | US20110021583 Enhanced transmucosal composition and dosage form |
| 01/27/2011 | US20110021582 Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 01/27/2011 | US20110021581 Dosing regimen for a selective s1p1 receptor agonist |
| 01/27/2011 | US20110021579 Peritoneum protecting agent |
| 01/27/2011 | US20110021578 Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine |
| 01/27/2011 | US20110021577 Aryloxy amine compounds and their use as sodium channel modulators |
| 01/27/2011 | US20110021576 Novel process to prepare pioglitazone via several novel intermediates |
| 01/27/2011 | US20110021574 Anti-cancer compounds, synthesis thereof, and methods of using same |
| 01/27/2011 | US20110021573 Antagonists of prostaglandin d2 receptors |
| 01/27/2011 | US20110021571 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| 01/27/2011 | US20110021570 Pyridone glucokinase activators |